Current Trends in Ligand Binding Real-Time Measurement Technologies.
Numerous advances in ligand binding assay (LBA) real-time measurement technologies have been made within the last several years, ranging from the development of novel platforms to drive technology expansion to the adaptation of existing platforms to optimize performance and throughput. In this review, we have chosen to focus on technologies that provide increased value to two distinct segments of the LBA community. First, experimentally, by measuring real-time binding events, these technologies provide data that can be used to interrogate receptor/ligand binding interactions. While overall the platforms are not new, they have made significant advances in throughput, multiplexing, and/or sensitivity. Second, clinically, these point-of-care (POC) technologies provide instantaneous information which facilitates rapid treatment decisions.
Pfizer, Eastern Point Rd, Groton, Connecticut, 06340, USA. Stephanie.Fraser@pfizer.com.
Stephanie
0000-0002-1946-9402
S
Fraser
Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, 91320, USA.
Judy Y
JY
Shih
Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477, USA.
Mark
M
Ware
AegisBioconsult, 78 Marbern Dr., Suffield, Connecticut, 06078, USA.
Edward
E
O'Connor
Lumigen, 22900 8 Mile Road, Southfield, Michigan, 48033, USA.
Mark J
MJ
Cameron
MedImmune, 319 N. Bernardo Ave, Mountain View, California, 94043, USA.
Martin
M
Schwickart
Merck Research Laboratories, Rahway, New Jersey, 07065, USA.
Xuemei
X
Zhao
Boehringer Ingelheim, 6701 Kaiser Drive, Fremont, California, 94555, USA.
Karin
K
Regnstrom
D001671:Biochemistry / Q000295:instrumentation / Q000639:trends*; D056656:Lab-On-A-Chip Devices; D058525:Quartz Crystal Microbalance Techniques; D020349:Surface Plasmon Resonance
emergent technology review; lateral flow immunoassay; ligand binding assay; real-time measurement; surface plasmon resonance